Antigen ID	TAR0FPXYP
Antigen Name	Undisclosed
Gene Name	Undisclosed

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Monoclonal antibody 45-2D9-haematoporphyrin conjugate	Hematoporphyrin	Undisclosed	Undisclosed	[1]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	Monoclonal antibody SN7-ricin chain A conjugate	Deglycosylated ricin A-chain (dgA)	Undisclosed	Undisclosed	[2]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	ROS-responsive SN38 ADC	Active metabolite of irinotecan SN38	DNA topoisomerase 1 (TOP1)	Mal-Cyc-PEG3-DAB	[3]
ADC Info	VL-DAB31-SN38	Active metabolite of irinotecan SN38	DNA topoisomerase 1 (TOP1)	Mal-Cyc-PEG3-DAB	[3]

ADC Info	ADC Name	Payload	Target	Linker	Ref
ADC Info	DB-1202	Undisclosed	Unclear	Undisclosed	[4]
ADC Info	CPO-204	Undisclosed	Unclear	Undisclosed	[5]
ADC Info	DXC-009	Undisclosed	Unclear	Undisclosed	[6]
ADC Info	MG-1901	Undisclosed	Unclear	Undisclosed	[7]
ADC Info	MG-2001	Undisclosed	Unclear	Undisclosed	[7]
ADC Info	MG-2002A	Undisclosed	Unclear	Undisclosed	[7]
ADC Info	PHN-010	DNA topoisomerase-I inhibitor	DNA topoisomerase 1 (TOP1)	Undisclosed	[8]
ADC Info	SC-005	PDB	Human Deoxyribonucleic acid (hDNA)	Undisclosed
ADC Info	SC-007	Undisclosed	Unclear	Undisclosed	[9]
ADC Info	131I-ImmuRAIT-HCG	Undisclosed	Undisclosed	Undisclosed	[10]
ADC Info	NBT-588	Undisclosed	Undisclosed	Undisclosed	[11]
ADC Info	NBT-588	Undisclosed	Undisclosed	Undisclosed	[11]
ADC Info	3-NAntC	Undisclosed	Undisclosed	Undisclosed	[12]
ADC Info	AbGn-108	Undisclosed	Undisclosed	Undisclosed	[13]
ADC Info	AccuADC-001	Undisclosed	Undisclosed	Undisclosed	[14]
ADC Info	ADC project 4 (Suzhou Medilink Therapeutics Ltd.)	Undisclosed	Undisclosed	Undisclosed	[15]
ADC Info	ADC project 5 (Suzhou Medilink Therapeutics Ltd.)	Undisclosed	Undisclosed	Undisclosed	[15]
ADC Info	ADC project 6 (Suzhou Medilink Therapeutics Ltd.)	Undisclosed	Undisclosed	Undisclosed	[15]
ADC Info	ADC project 7 (Suzhou Medilink Therapeutics Ltd.)	Undisclosed	Undisclosed	Undisclosed	[15]
ADC Info	ADC001 (Arbele)	Undisclosed	Undisclosed	Undisclosed	[16]
ADC Info	ADC002 (Arbele)	Undisclosed	Undisclosed	Undisclosed	[16]
ADC Info	ADC003 (Arbele)	Undisclosed	Undisclosed	Undisclosed	[16]
ADC Info	ADC2154	Undisclosed	Undisclosed	Undisclosed	[17]
ADC Info	ADC2231	Undisclosed	Undisclosed	Undisclosed	[18]
ADC Info	ADC2313	Undisclosed	Undisclosed	Undisclosed	[19]
ADC Info	ADC2317	Undisclosed	Undisclosed	Undisclosed	[20]
ADC Info	ADC2335	Undisclosed	Undisclosed	Undisclosed	[21]
ADC Info	Additional antibody drug conjugate (Virtuoso Therapeutics)	Undisclosed	Undisclosed	Undisclosed	[22]
ADC Info	ADRX-863	Undisclosed	Undisclosed	Undisclosed	[23]
ADC Info	Advanced antibody drug conjugate (Belrose Pharma)	Undisclosed	Undisclosed	Undisclosed	[24]
ADC Info	AK 30 NGF	Undisclosed	Undisclosed	Undisclosed	[25]
ADC Info	Alpha-amanitin antibody-drug conjugate (Agensys)	Alpha-amanitin	DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)	Undisclosed	[26]
ADC Info	AMB-015	Undisclosed	Undisclosed	Undisclosed	[27]
ADC Info	AMB-101	Topoisomerase I inhibitor	DNA topoisomerase 1 (TOP1)	Undisclosed	[28]
ADC Info	AMB-102	Undisclosed	Undisclosed	Undisclosed	[29]
ADC Info	ANG-101	Undisclosed	Undisclosed	Undisclosed	[30]
ADC Info	Antibody boron conjugate radiopharmaceuticals (TAE Life Sciences)	Undisclosed	Undisclosed	Undisclosed	[31]
ADC Info	Antibody drug conjugate (Halozyme)	Undisclosed	Undisclosed	Undisclosed	[32]
ADC Info	Antibody drug conjugate containing duocarmycin analogue	Undisclosed	Undisclosed	Undisclosed	[33]
ADC Info	Antibody targeted amanitin conjugate	Alpha-amanitin	DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)	Undisclosed	[34]
ADC Info	Antibody-drug conjugate (Oxford BioTherapeutics/Boehringer Ingelheim)	Undisclosed	Undisclosed	Undisclosed	[35]
ADC Info	Antibody-drug conjugate (Sanofi/Seagen)	Undisclosed	Undisclosed	Undisclosed	[36]
ADC Info	Antibody-drug conjugate (SynAffix)	Undisclosed	Undisclosed	Undisclosed	[37]
ADC Info	Antibody-drug conjugate 3 (Synthon)	Undisclosed	Undisclosed	Undisclosed	[38]
ADC Info	Antibody-drug conjugate 4 (Synthon)	Undisclosed	Undisclosed	Undisclosed	[39]
ADC Info	Antibody-drug conjugate containing OXS-2175 (Oxis Biotech/MultiCell ImmunoTherapeutics)	Undisclosed	Undisclosed	Undisclosed	[40]
ADC Info	Anticancer antibody-drug conjugate (Vaccinex/Catalent Pharma Solutions)	Undisclosed	Undisclosed	Undisclosed	[41]
ADC Info	Anti-cancer therapeutic (Amgen)	Undisclosed	Undisclosed	Undisclosed	[42]
ADC Info	Antiviral Fc-conjugate (Cidara Therapeutics)	Undisclosed	Undisclosed	Undisclosed	[43]
ADC Info	APB-CS	Undisclosed	Undisclosed	Undisclosed	[44]
ADC Info	APEC-2	Undisclosed	Undisclosed	Undisclosed	[45]
ADC Info	APEC-3	Undisclosed	Undisclosed	Undisclosed	[46]
ADC Info	APH-0912	Docetaxel	Microtubule (MT)	Hydrophilic linker containing sugar molecules	[47]
ADC Info	AR081	Undisclosed	Undisclosed	Undisclosed	[48]
ADC Info	AT-00	Undisclosed	Undisclosed	Undisclosed	[49]
ADC Info	AT-01	Undisclosed	Undisclosed	Undisclosed	[50]
ADC Info	AT-03	Undisclosed	Undisclosed	Undisclosed	[50]
ADC Info	AT-04	Undisclosed	Undisclosed	Undisclosed	[50]
ADC Info	AU-011	IRDye 700DX	Undisclosed	Undisclosed	[51]
ADC Info	AVP20	Undisclosed	Undisclosed	Undisclosed	[52]
ADC Info	BB-1706	Undisclosed	Undisclosed	Undisclosed	[53]
ADC Info	BB-1708	Undisclosed	Undisclosed	Undisclosed	[53]
ADC Info	BB-1710	Undisclosed	Undisclosed	Undisclosed	[53]
ADC Info	BB-1712	Undisclosed	Undisclosed	Undisclosed	[53]
ADC Info	BC5084	Undisclosed	Undisclosed	Undisclosed	[54]
ADC Info	BIO103	Undisclosed	Undisclosed	Undisclosed	[55]
ADC Info	BIO104	Undisclosed	Undisclosed	Undisclosed	[55]
ADC Info	BIO105	Undisclosed	Undisclosed	Undisclosed	[56]
ADC Info	BIO-107	Undisclosed	Undisclosed	Undisclosed	[57]
ADC Info	BIO-108	Undisclosed	Undisclosed	Undisclosed	[57]
ADC Info	BIO-109	Undisclosed	Undisclosed	Undisclosed	[57]
ADC Info	BIO-110	Undisclosed	Undisclosed	Undisclosed	[57]
ADC Info	BIO-112	Undisclosed	Undisclosed	Undisclosed	[57]
ADC Info	BIO-201	Undisclosed	Undisclosed	Undisclosed	[57]
ADC Info	BIOO-1	Undisclosed	Undisclosed	Undisclosed	[58]
ADC Info	BIOO-2	Undisclosed	Undisclosed	Undisclosed	[59]
ADC Info	BIOO-3	Undisclosed	Undisclosed	Undisclosed	[60]
ADC Info	BIOO-4	Undisclosed	Undisclosed	Undisclosed	[61]
ADC Info	Bi-specific antibody drug conjugate	Undisclosed	Undisclosed	Undisclosed	[62]
ADC Info	BL-B029A1	Undisclosed	Undisclosed	Undisclosed	[63]
ADC Info	BL-M002A2	Undisclosed	Undisclosed	Undisclosed	[64]
ADC Info	BL-M005	Undisclosed	Undisclosed	Undisclosed	[65]
ADC Info	BL-M005A2	Dual-warhead	Undisclosed	Undisclosed	[66]
ADC Info	BL-M22D1	Undisclosed	Undisclosed	Undisclosed	[67]
ADC Info	BL-M25D1	Undisclosed	Undisclosed	Undisclosed	[67]
ADC Info	BMT-125961	Undisclosed	Undisclosed	Undisclosed	[68]
ADC Info	BP-A102	Undisclosed	Undisclosed	Undisclosed	[69]
ADC Info	BP-A103	Undisclosed	Undisclosed	Undisclosed	[69]
ADC Info	BR107	Undisclosed	Undisclosed	Undisclosed	[70]
ADC Info	BR109	Undisclosed	Undisclosed	Undisclosed	[71]
ADC Info	BR-2003	Undisclosed	Undisclosed	Undisclosed	[53]
ADC Info	BR-2102	Undisclosed	Undisclosed	Undisclosed	[53]
ADC Info	BR-2202	Undisclosed	Undisclosed	Undisclosed	[53]
ADC Info	BRKB-28	Undisclosed	Undisclosed	Undisclosed	[72]
ADC Info	BRKB-44	Undisclosed	Undisclosed	Undisclosed	[73]
ADC Info	BRY811	Undisclosed	Undisclosed	Undisclosed	[74]
ADC Info	BsAb-ADC (Medilink Therapeutics)	Undisclosed	Undisclosed	Undisclosed	[75]
ADC Info	BSC-4101	Undisclosed	Undisclosed	Undisclosed	[76]
ADC Info	BSC-4201	Undisclosed	Undisclosed	Undisclosed	[77]
ADC Info	BSI-023	Undisclosed	Undisclosed	Undisclosed	[78]
ADC Info	CAT-03-106	Undisclosed	Undisclosed	Undisclosed	[79]
ADC Info	CBP-1609	Undisclosed	Undisclosed	Undisclosed	[80]
ADC Info	CBX-13	Mertansine DM4	Microtubule (MT)	Undisclosed	[81]
ADC Info	CBX-14	Multi-targetd DDR inhibitor	Epithelial discoidin domain-containing receptor 1 (DDR1)	Undisclosed	[81]
ADC Info	CM-09	Undisclosed	Undisclosed	Undisclosed	[82]
ADC Info	CO-1003	Undisclosed	Undisclosed	Undisclosed	[83]
ADC Info	CO-1023	Undisclosed	Undisclosed	Undisclosed	[83]
ADC Info	CRB-2107	Undisclosed	Undisclosed	Undisclosed	[84]
ADC Info	CS-5002	Undisclosed	Undisclosed	Undisclosed	[85]
ADC Info	CS5005	Undisclosed	Undisclosed	Undisclosed	[86]
ADC Info	CS5006	Undisclosed	Undisclosed	Undisclosed	[86]
ADC Info	CT-P26	Undisclosed	Undisclosed	Undisclosed	[87]
ADC Info	DBAF-301	Undisclosed	Undisclosed	Undisclosed	[88]
ADC Info	DN-027	Undisclosed	Undisclosed	Undisclosed	[89]
ADC Info	DN-028	Undisclosed	Undisclosed	Undisclosed	[90]
ADC Info	DOM-1314	Undisclosed	Undisclosed	Undisclosed	[91]
ADC Info	Dual-payload ADC (Mersana Therapeutics)	AF-HPA+DNA monoalkylator I-BiP	Microtubule (MT); Human Deoxyribonucleic acid (hDNA)	Undisclosed	[92]
ADC Info	DXC-010	Undisclosed	Undisclosed	Undisclosed	[6]
ADC Info	DXC-011	Undisclosed	Undisclosed	Undisclosed	[6]
ADC Info	DXC-012	Undisclosed	Undisclosed	Undisclosed	[6]
ADC Info	DXC-013	Undisclosed	Undisclosed	Undisclosed	[6]
ADC Info	DXC-014	Undisclosed	Undisclosed	Undisclosed	[6]
ADC Info	DXC-015	Undisclosed	Undisclosed	Undisclosed	[6]
ADC Info	DXC-016	Undisclosed	Undisclosed	Undisclosed	[6]
ADC Info	DXC-017	Undisclosed	Undisclosed	Undisclosed	[6]
ADC Info	DXC-018	Undisclosed	Undisclosed	Undisclosed	[6]
ADC Info	DXC-019	Undisclosed	Undisclosed	Undisclosed	[6]
ADC Info	DXC-020	Undisclosed	Undisclosed	Undisclosed	[6]
ADC Info	EP-400	Undisclosed	Undisclosed	Undisclosed	[93]
ADC Info	Eribulin ADC (Jiangsu hengrui)	Eribulin	Microtubule (MT)	Undisclosed	[94]
ADC Info	EVOLVE-104 ADC	Undisclosed	Undisclosed	Undisclosed	[95]
ADC Info	EX108	Undisclosed	Undisclosed	Undisclosed	[96]
ADC Info	FG-B310	Undisclosed	Undisclosed	Undisclosed	[97]
ADC Info	FG-M131	Undisclosed	Undisclosed	Undisclosed	[97]
ADC Info	G-100 (Magenta Therapeutics)	Undisclosed	Undisclosed	Undisclosed	[98]
ADC Info	GBM-12401	Undisclosed	Undisclosed	Undisclosed	[99]
ADC Info	GF-2014	Undisclosed	Undisclosed	Undisclosed	[100]
ADC Info	GL-231	Undisclosed	Undisclosed	Undisclosed	[101]
ADC Info	Glaucoma therapy	Undisclosed	Undisclosed	Undisclosed	[102]
ADC Info	GMA-205	Undisclosed	Undisclosed	Undisclosed	[103]
ADC Info	GMA-305	Undisclosed	Undisclosed	Undisclosed	[104]
ADC Info	GQ-1009	Undisclosed	Undisclosed	Undisclosed	[105]
ADC Info	GQ1011	Undisclosed	Undisclosed	Undisclosed	[105]
ADC Info	GR-1014	Undisclosed	Undisclosed	Undisclosed	[105]
ADC Info	GR-1015	Undisclosed	Undisclosed	Undisclosed	[105]
ADC Info	GR-1016	Undisclosed	Undisclosed	Undisclosed	[105]
ADC Info	GR1018	Undisclosed	Undisclosed	Undisclosed	[105]
ADC Info	HDP-104	Undisclosed	Undisclosed	Undisclosed	[106]
ADC Info	HY-0001	Undisclosed	Undisclosed	Undisclosed	[107]
ADC Info	IBI130	Undisclosed	Undisclosed	Undisclosed	[108]
ADC Info	IKS-02	Undisclosed	Undisclosed	Undisclosed	[109]
ADC Info	IKS-04	Undisclosed	Undisclosed	Undisclosed	[109]
ADC Info	IMB-202	Undisclosed	Undisclosed	Undisclosed	[110]
ADC Info	IMB-212	Undisclosed	Undisclosed	Undisclosed	[111]
ADC Info	IMB-213I	Undisclosed	Undisclosed	Undisclosed	[111]
ADC Info	IN30718	Undisclosed	Undisclosed	Undisclosed	[112]
ADC Info	IN30728	Undisclosed	Undisclosed	Undisclosed	[113]
ADC Info	IOG-101	Undisclosed	Undisclosed	Undisclosed	[114]
ADC Info	JY-023	Undisclosed	Undisclosed	Undisclosed	[115]
ADC Info	JY208	Undisclosed	Undisclosed	Undisclosed	[116]
ADC Info	JY210	Undisclosed	Undisclosed	Undisclosed	[116]
ADC Info	KGX201	Undisclosed	Undisclosed	Undisclosed	[117]
ADC Info	LCB-02A	Undisclosed	Undisclosed	Undisclosed	[118]
ADC Info	LCB-04A	Undisclosed	Undisclosed	Undisclosed	[118]
ADC Info	LCB-06A	Undisclosed	Undisclosed	Undisclosed	[118]
ADC Info	LCB-09A	Undisclosed	Undisclosed	Undisclosed	[118]
ADC Info	LCB-12A	Undisclosed	Undisclosed	Undisclosed	[118]
ADC Info	LCB14-15nm	Undisclosed	Undisclosed	Undisclosed	[119]
ADC Info	LCB-18A	Undisclosed	Undisclosed	Undisclosed	[118]
ADC Info	LCB-19A	Undisclosed	Undisclosed	Undisclosed	[118]
ADC Info	LCB-20A	Undisclosed	Undisclosed	Undisclosed	[118]
ADC Info	LCB-42A	Undisclosed	Undisclosed	Undisclosed	[118]
ADC Info	LCB-69	Undisclosed	Undisclosed	Undisclosed	[118]
ADC Info	LCB-85	Undisclosed	Undisclosed	Undisclosed	[118]
ADC Info	LCB-88	Undisclosed	Undisclosed	Undisclosed	[120]
ADC Info	LCB-91	Undisclosed	Undisclosed	Undisclosed	[118]
ADC Info	LD016	Undisclosed	Undisclosed	Undisclosed	[121]
ADC Info	LEAD ADC (Virtuoso Therapeutics)	Undisclosed	Undisclosed	Undisclosed	[122]
ADC Info	LM-001	Undisclosed	Undisclosed	Undisclosed	[123]
ADC Info	LM-004	Undisclosed	Undisclosed	Undisclosed	[123]
ADC Info	LM-005	Undisclosed	Undisclosed	Undisclosed	[123]
ADC Info	LM-006	Undisclosed	Undisclosed	Undisclosed	[123]
ADC Info	LM-007	Undisclosed	Undisclosed	Undisclosed	[123]
ADC Info	LM-008	Undisclosed	Undisclosed	Undisclosed	[123]
ADC Info	LM-317	Undisclosed	Undisclosed	Undisclosed	[124]
ADC Info	LP-A18	Undisclosed	Undisclosed	Undisclosed	[125]
ADC Info	M-131	Undisclosed	Undisclosed	Undisclosed	[126]
ADC Info	MABS-01	Undisclosed	Undisclosed	Undisclosed	[127]
ADC Info	MABS-02	Undisclosed	Undisclosed	Undisclosed	[127]
ADC Info	Masked ADC (Adagene/ADC Therapeutics)	PBD dimer	Human Deoxyribonucleic acid (hDNA)	Undisclosed	[128]
ADC Info	MBC-301	Undisclosed	Undisclosed	Undisclosed	[129]
ADC Info	MBK-101	Undisclosed	Undisclosed	Undisclosed	[130]
ADC Info	MG2002B	Undisclosed	Undisclosed	Undisclosed	[7]
ADC Info	MG2011C	Undisclosed	Undisclosed	Undisclosed	[7]
ADC Info	MG2018	Undisclosed	Undisclosed	Undisclosed	[7]
ADC Info	MG2106E	Undisclosed	Undisclosed	Undisclosed	[7]
ADC Info	Monoclonal Antibody-Drug Conjugate (Antengene)	Undisclosed	Undisclosed	Undisclosed	[131]
ADC Info	Monoclonal Antibody-Drug conjugate (Celltrion Chemical Research Institute/Immunogen/Celltrion)	Undisclosed	Undisclosed	Undisclosed	[132]
ADC Info	Monoclonal Antibody-Drug Conjugate (Kind Pharmaceuticals)	Undisclosed	Undisclosed	Undisclosed	[133]
ADC Info	MRG-006	Undisclosed	Undisclosed	Undisclosed	[134]
ADC Info	MRX-23	Undisclosed	Undisclosed	Undisclosed	[135]
ADC Info	NBE-001	Undisclosed	Undisclosed	Undisclosed	[136]
ADC Info	NBE-003	Undisclosed	Undisclosed	Undisclosed	[137]
ADC Info	NBT-528	Undisclosed	Undisclosed	Undisclosed	[138]
ADC Info	NBT-568	Undisclosed	Undisclosed	Undisclosed	[139]
ADC Info	NBT-578	Undisclosed	Undisclosed	Undisclosed	[140]
ADC Info	NBT-598	Undisclosed	Undisclosed	Undisclosed	[141]
ADC Info	Next generation antibody-drug conjugate (Oxford BioTherapeutics)	Undisclosed	Undisclosed	Undisclosed	[142]
ADC Info	NTX-1107	Undisclosed	Undisclosed	Undisclosed	[143]
ADC Info	NW-001	Undisclosed	Undisclosed	Undisclosed	[144]
ADC Info	NW-12-005	Undisclosed	Undisclosed	Undisclosed	[145]
ADC Info	NX-08	Undisclosed	Undisclosed	Undisclosed	[146]
ADC Info	OBT029	Undisclosed	Undisclosed	Undisclosed	[147]
ADC Info	OBT207	Undisclosed	Undisclosed	Undisclosed	[147]
ADC Info	OBT542	Undisclosed	Undisclosed	Undisclosed	[147]
ADC Info	OTV:CH2	Undisclosed	Undisclosed	Undisclosed	[148]
ADC Info	OTV:LF3	Undisclosed	Undisclosed	Undisclosed	[148]
ADC Info	OX-004	Undisclosed	Undisclosed	Undisclosed	[149]
ADC Info	P-1000	Undisclosed	Undisclosed	Undisclosed	[150]
ADC Info	P-BsAb-ADC	Undisclosed	Undisclosed	Undisclosed	[151]
ADC Info	PBX-002	Undisclosed	Undisclosed	Undisclosed	[152]
ADC Info	PCG-C002	Undisclosed	Undisclosed	Undisclosed	[153]
ADC Info	PCG-C004	Undisclosed	Undisclosed	Undisclosed	[153]
ADC Info	PCG-C006	Undisclosed	Undisclosed	Undisclosed	[153]
ADC Info	PCG-N003	Undisclosed	Undisclosed	Undisclosed	[153]
ADC Info	PHN-020	Undisclosed	Undisclosed	Undisclosed	[8]
ADC Info	PLBA-001	Undisclosed	Undisclosed	Undisclosed	[154]
ADC Info	PLBA-002	Undisclosed	Undisclosed	Undisclosed	[154]
ADC Info	PLBA-003	Undisclosed	Undisclosed	Undisclosed	[154]
ADC Info	PLBA-004	Undisclosed	Undisclosed	Undisclosed	[154]
ADC Info	PLBA-005	Undisclosed	Undisclosed	Undisclosed	[154]
ADC Info	PLBC-001	Undisclosed	Undisclosed	Undisclosed	[154]
ADC Info	PLBC-002	Undisclosed	Undisclosed	Undisclosed	[154]
ADC Info	PLBC-003	Undisclosed	Undisclosed	Undisclosed	[154]
ADC Info	PSM-101	Undisclosed	Undisclosed	Undisclosed	[155]
ADC Info	PTM-001-ADC	Mertansine DM1	Microtubule (MT)	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)	[156]
ADC Info	RAD-501	Undisclosed	Undisclosed	Undisclosed	[157]
ADC Info	RC-168	Undisclosed	Undisclosed	Undisclosed	[158]
ADC Info	RC-178	Undisclosed	Undisclosed	Undisclosed	[158]
ADC Info	RC-188	Undisclosed	Undisclosed	Undisclosed	[158]
ADC Info	SAB-Y1	Undisclosed	Undisclosed	Undisclosed	[159]
ADC Info	SAB-Y17	Undisclosed	Undisclosed	Undisclosed	[159]
ADC Info	SDV-1001	Undisclosed	Undisclosed	Undisclosed	[160]
ADC Info	Second ADC (Virtuoso Therapeutics)	Undisclosed	Undisclosed	Undisclosed	[161]
ADC Info	SeeloMab-GEX	Undisclosed	Undisclosed	Undisclosed	[162]
ADC Info	SGN-25	Undisclosed	Undisclosed	Undisclosed	[163]
ADC Info	SIB-004A	Undisclosed	Undisclosed	Undisclosed	[164]
ADC Info	SIM-002A	Undisclosed	Undisclosed	Undisclosed	[165]
ADC Info	SIM-005A	Undisclosed	Undisclosed	Undisclosed	[166]
ADC Info	SMD-3117	Undisclosed	Undisclosed	Undisclosed	[167]
ADC Info	SMD-5033	Undisclosed	Undisclosed	Undisclosed	[168]
ADC Info	SMP-190	DX-8951 derivative (DXd)	DNA topoisomerase 1 (TOP1)	Unique hydrophilic Linker	[169]
ADC Info	SO-N107	Undisclosed	Undisclosed	Undisclosed	[170]
ADC Info	SOT106	Undisclosed	Undisclosed	Undisclosed	[171]
ADC Info	Spliceostatin-antibody-drug conjugate	Spliceostatin A	Splicing factor 3B subunit 1 (SF3B1)	Undisclosed	[172]
ADC Info	STING agonist ADC	STING agonist	Stimulator of interferon genes protein (STING1)	Undisclosed	[173]
ADC Info	STING based antibody-drug conjugate (Exelixis)	STING agonist	Stimulator of interferon genes protein (STING1)	Undisclosed	[174]
ADC Info	SY-0625	Undisclosed	Undisclosed	Undisclosed	[175]
ADC Info	SY-0831	Undisclosed	Undisclosed	Undisclosed	[175]
ADC Info	SY-0833	Undisclosed	Undisclosed	Undisclosed	[175]
ADC Info	SY-1211	Undisclosed	Undisclosed	Undisclosed	[175]
ADC Info	SY-1274	Undisclosed	Undisclosed	Undisclosed	[175]
ADC Info	SY-1330	Undisclosed	Undisclosed	Undisclosed	[175]
ADC Info	SY-1558	Undisclosed	Undisclosed	Undisclosed	[176]
ADC Info	SY-1700	Undisclosed	Undisclosed	Undisclosed	[175]
ADC Info	TAE-020	Undisclosed	Undisclosed	Undisclosed	[177]
ADC Info	TAK-ATACs	Alpha-amanitin	DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)	Undisclosed	[178]
ADC Info	TGM-002	Undisclosed	Undisclosed	Undisclosed	[179]
ADC Info	TGM-003	Undisclosed	Undisclosed	Undisclosed	[180]
ADC Info	TGM-004	Undisclosed	Undisclosed	Undisclosed	[181]
ADC Info	TGM-005	Undisclosed	Undisclosed	Undisclosed	[182]
ADC Info	TST013	Undisclosed	Undisclosed	Undisclosed	[183]
ADC Info	TT-01	Undisclosed	Undisclosed	Undisclosed	[184]
ADC Info	TUB-050	Undisclosed	Undisclosed	Undisclosed	[185]
ADC Info	TUB-060	Undisclosed	Undisclosed	Undisclosed	[185]
ADC Info	Vas-201	Undisclosed	Undisclosed	Undisclosed	[186]
ADC Info	Vas-202	Undisclosed	Undisclosed	Undisclosed	[187]
ADC Info	VIS-705	Undisclosed	Undisclosed	Undisclosed	[188]
ADC Info	VLS-201	Undisclosed	Undisclosed	Undisclosed	[189]
ADC Info	VLS-301	Undisclosed	Undisclosed	Undisclosed	[190]
ADC Info	WTX-116	Undisclosed	Undisclosed	Undisclosed	[191]
ADC Info	WTX-222	Undisclosed	Undisclosed	Undisclosed	[191]
ADC Info	WTX-231	Undisclosed	Undisclosed	Undisclosed	[191]
ADC Info	XMT-2068	STING agonist	Stimulator of interferon genes protein (STING1)	Undisclosed	[192]
ADC Info	XMT-2175	STING agonist	Stimulator of interferon genes protein (STING1)	Undisclosed	[192]
ADC Info	XNW-28012	Undisclosed	Undisclosed	Undisclosed	[193]
ADC Info	XYD-9668-198	Undisclosed	Undisclosed	Undisclosed	[194]
ADC Info	ZV03-ADC	Undisclosed	Undisclosed	Undisclosed	[195]
ADC Info	Antibody drug conjugate (Asana BioSciences)	Undisclosed	Undisclosed	Undisclosed	[196]
ADC Info	Antibody drug conjugate (Compugen)	Undisclosed	Undisclosed	Undisclosed	[197]
ADC Info	Antibody drug conjugate (Five Prime cancer)	Undisclosed	Undisclosed	Undisclosed	[198]
ADC Info	Antibody drug conjugate (Intrexon)	Undisclosed	Undisclosed	Undisclosed	[199]
ADC Info	Antibody drug conjugate (Meditope Biosciences)	Undisclosed	Undisclosed	Undisclosed	[200]
ADC Info	Antibody drug conjugate (Sanofi)	Undisclosed	Undisclosed	Undisclosed	[201]
ADC Info	Antibody-drug conjugate (Bristol-Myers Squibb)	Undisclosed	Undisclosed	Undisclosed	[202]
ADC Info	Antibody-drug conjugate (Daiichi Sankyo)	Undisclosed	Undisclosed	Undisclosed	[203]
ADC Info	Antibody-drug conjugate (University of Toronto/Advanced Proteome Therapeutics)	Undisclosed	Undisclosed	Undisclosed	[204]
ADC Info	Antibody-drug conjugate (University of Toronto/ImmunoBiochem)	Undisclosed	Undisclosed	Undisclosed	[205]
ADC Info	Antibody-drug conjugate therapy (Neoantigenics)	Undisclosed	Undisclosed	Undisclosed	[206]
ADC Info	BIOO-5	Undisclosed	Undisclosed	Undisclosed	[207]
ADC Info	BIOO-6	Undisclosed	Undisclosed	Undisclosed	[208]
ADC Info	BIOO-7	Undisclosed	Undisclosed	Undisclosed	[209]
ADC Info	CRC-02 targeting antibody-drug conjugate	Undisclosed	Undisclosed	Undisclosed	[210]
ADC Info	CYP-Ab	Undisclosed	Undisclosed	Undisclosed	[211]
ADC Info	KSI-201	Undisclosed	Undisclosed	Undisclosed	[212]
ADC Info	LCB14-2nm	Undisclosed	Undisclosed	Undisclosed	[213]
ADC Info	LIN-003	Undisclosed	Undisclosed	Undisclosed	[214]
ADC Info	Marine-derived cytotoxic payloads antibody-drug conjugation	Undisclosed	Undisclosed	Undisclosed	[215]
ADC Info	Monovalent Azymatic Antibody Drug Conjugate (Zymeworks)	Undisclosed	Undisclosed	Undisclosed	[216]
ADC Info	MRG-005	Undisclosed	Undisclosed	Undisclosed	[217]
ADC Info	MRG-007	Undisclosed	Undisclosed	Undisclosed	[218]
ADC Info	MRG-008	Undisclosed	Undisclosed	Undisclosed	[219]
ADC Info	MRG-009	Undisclosed	Undisclosed	Undisclosed	[220]
ADC Info	Multi-functional antibody drug conjugate combination therapeutics (Sutro Biopharma/Celgene)	Undisclosed	Undisclosed	Undisclosed	[221]

Ref 1	Targetted phototherapy with sensitizer-monoclonal antibody conjugate and light. Surg Oncol. 1993;2(1):31-42. doi: 10.1016/0960-7404(93)90042-w.
Ref 2	Development of a severe combined immunodeficiency (SCID) mouse model consisting of highly disseminated human B-cell leukemia/lymphoma, cure of the tumors by systemic administration of immunotoxin, and development/application of a clonotype-specific polymerase chain reaction-based assay. Cancer Res. 1997 Feb 15;57(4):678-85.
Ref 3	Diazaborines Are a Versatile Platform to Develop ROS-Responsive Antibody Drug Conjugates*. Angew Chem Int Ed Engl. 2021 Dec 1;60(49):25914-25921. doi: 10.1002/anie.202109835. Epub 2021 Nov 5.
Ref 4	A Study of DB-1202 Monotherapy in Advanced Solid Tumors.
Ref 5	Antibody-drug conjugate CPO204 obtains clinical trial approval in the U.S.
Ref 6	DAC biotechnology company product pipeline
Ref 7	MabGen biotechnology company product pipeline
Ref 8	Pheno therapeutics product pipeline
Ref 9	Prospective grant of an exclusive patent license: anti-CD56 as an antibody-drug conjugate or non-ADC to target glioblastoma either alone or in combination with other potential immuno-oncology drugs; 2020
Ref 10	Introduction to basic information on ADC drug 131I-ImmuRAIT-HCG (Immunomedics).
Ref 11	NewBio Therapeutics company product pipeline
Ref 12	Introduction to basic information on ADC drug 3-NAntC
Ref 13	ADC review: basic information about ABGN-108.
Ref 14	Defence Therapeutics company product pipeline in Development.
Ref 15	Medilink biotechnology company product pipeline
Ref 16	Arbelebio R&D pipeline.
Ref 17	Introduction to basic information on ADC drug ADC2154
Ref 18	Introduction to basic information on ADC drug ADC2231
Ref 19	Introduction to basic information on ADC drug ADC2313
Ref 20	Introduction to basic information on ADC drug ADC2317
Ref 21	Introduction to basic information on ADC drug ADC2335
Ref 22	Introduction to basic information on ADC drug additional ADCs (Virtuoso Therapeutics).
Ref 23	Adcentrx therapeutics product pipeline
Ref 24	Introduction to basic information on advanced antibody drug conjugates(Belrose Pharma).
Ref 25	Introduction to basic information on ADC drug AK 30 NGF; 27 Nov 2000.
Ref 26	Introduction to basic information on alpha-amanitin antibody-drug conjugates(Agensys).
Ref 27	AIMEDBIO biotechnology company product pipeline.
Ref 28	Introduction to basic information on ADC drug AMB-101
Ref 29	AmMax biotechnology company product pipeline
Ref 30	Introduction to basic information on monoclonal antibody-drug conjugate(Antengene).
Ref 31	TAE Life Sciences company product pipeline
Ref 32	Research programme : antibody drug conjugate-Halozyme; 28 Feb 2021.
Ref 33	Introduction to basic information on ADC drug Antibody drug conjugate containing duocarmycin analogue
Ref 34	Combination of antibody-targeted amanitin conjugates (ATAC) with immune checkpoint inhibitors shows synergistic therapeutic effect in vitro and in vivo. Cancer Res (2021) 81 (13_Supplement): 921.
Ref 35	Oxford biotherapeutics and boehringer ingelheim agree on 2 year extension to their second multi-year collaboration in cancer immunology; 2023
Ref 36	Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates; 2022
Ref 37	Synaffix is a biotechnology company product pipeline
Ref 38	Introduction to basic information on antibody-drug conjugate 3(Synthon).
Ref 39	Introduction to basic information on antibody-drug conjugate 4(Synthon).
Ref 40	Introduction to basic information on ADC drug antibody-drug conjugate containing OXS-2175(Oxis Biotech/MultiCell ImmunoTherapeutics).
Ref 41	Vaccinex and catalent biologics to collaborate on ADC development; 2017
Ref 42	Introduction to basic information on monoclonal anti-cancer therapeutic (Amgen).
Ref 43	Introduction to basic information on ADC drug Antiviral Fc-conjugates(Cidara Therapeutics).
Ref 44	Introduction to basic information on ADC drug APB-CS
Ref 45	Introduction to basic information on ADC drug APEC-2.
Ref 46	Introduction to basic information on ADC drug APEC-3.
Ref 47	Aphios biotechnology company product pipeline
Ref 48	Y-Biologics biotechnology company product pipeline
Ref 49	Introduction to basic information on ADC drug AT-00
Ref 50	Axcynsis therapeutics product pipeline
Ref 51	Immune checkpoint inhibition combined with targeted therapy using a novel virus-like drug conjugate induces complete responses in a murine model of local and distant tumors. Cancer Immunol Immunother. 2023 Jul;72(7):2405-2422. doi: 10.1007/s00262-023-03425-3. Epub 2023 Mar 30.
Ref 52	AVIPEP Therapeutics product pipeline
Ref 53	Bliss Biopharmaceutical company product pipeline
Ref 54	Introduction to basic information on ADC drug BC5084 by Veri.larvol.
Ref 55	boostimmune biotechnology company product pipeline
Ref 56	Boostimmune R&D pipeline.
Ref 57	Biocytogen biotechnology company product pipeline
Ref 58	Introduction to basic information on ADC drug BIOO-1.
Ref 59	Introduction to basic information on ADC drug BIOO-2.
Ref 60	Introduction to basic information on ADC drug BIOO-3.
Ref 61	Introduction to basic information on ADC drug BIOO-4.
Ref 62	Introduction to basic information on ADC drug bi-specific antibody drug conjugates(Zymeworks).
Ref 63	ADC review: basic information about BL-B029A1.
Ref 64	ADC review: basic information about BL-M002A2.
Ref 65	Introduction to basic information on ADC drug BL-M005.
Ref 66	ADC review: basic information about BL-M005A2.
Ref 67	Biokin pharma Prospectus; 2022
Ref 68	Introduction to basic information on ADC drug BMT-125961.
Ref 69	JINFA pharmaceutical company product pipeline
Ref 70	An overview of BR107.
Ref 71	Bioray R&D pipeline.
Ref 72	Brickbio biotechnology company product pipeline
Ref 73	Brickbio biotechnology company product pipeline
Ref 74	An overview of BRY811.
Ref 75	Introduction to basic information on BsAb-ADC (Medilink Therapeutics).
Ref 76	Introduction to basic information on ADC drug BSC-4101
Ref 77	Introduction to basic information on ADC drug BSC-4201.
Ref 78	Introduction to basic information on ADC drug BSI-023.
Ref 79	Introduction to basic information on ADC drug CAT-03-106.
Ref 80	Introduction to basic information on ADC drug CBP-1609.
Ref 81	Cybrexa therapeutics product pipeline
Ref 82	Introduction to basic information on ADC drug CM-09(Curemeta).
Ref 83	Progression towards the clinic by 2025 with a strategy for rapid FIH data acquisition.
Ref 84	Introduction to basic information on ADC drug CRB-2107.
Ref 85	Cstone pharma product pipeline
Ref 86	Cstonepharma R&D pipeline.
Ref 87	Introduction to basic information on ADC drug CT-P26.
Ref 88	Introduction to basic information on ADC drug DBAF-301.
Ref 89	Introduction to basic information on ADC drug DN-027.
Ref 90	Introduction to basic information on ADC drug DN-028.
Ref 91	Safety Assessment of Antibody Drug Conjugates.
Ref 92	An antibody-drug conjugate carrying a microtubule inhibitor and a DNA alkylator exerts both mechanisms of action on tumor cells. Cancer Res (2019) 79 (13_Supplement): 232.
Ref 93	ADC review: basic information about EP-400.
Ref 94	Introduction to basic information on eribulin ADC (Jiangsu hengrui)
Ref 95	EvolveImmune therapeutics product pipeline
Ref 96	Introduction to basic information on ADC drug EX108.
Ref 97	FutureGen R&D pipeline.
Ref 98	Introduction to basic information on ADC drug G-100 (Magenta Therapeutics).
Ref 99	Introduction to basic information on ADC drug Gbm12401.
Ref 100	Introduction to basic information on ADC drug GF-2014.
Ref 101	Introduction to basic information on ADC drug GL-231
Ref 102	Introduction to basic information on ADC drug glaucoma therapy(Houston).
Ref 103	Gmax biopharm biopharmaceutical company product pipeline
Ref 104	Introduction to basic information on ADC drug GMA-305.
Ref 105	Genequantum biopharmaceutical company product pipeline
Ref 106	Heidelberg pharma product pipeline
Ref 107	Huiyu pharma semi-annual report; 2022
Ref 108	Innoventbio 2022 Annual Performance Report.
Ref 109	Iksuda therapeutics product pipeline
Ref 110	ADC review IMB-202
Ref 111	Immunobiochem biotechnology company product pipeline
Ref 112	Introduction to basic information on ADC drug IN30718.
Ref 113	Inxmed R&D pipeline.
Ref 114	Introduction to basic information on ADC drug IOG-101.
Ref 115	Introduction to basic information on ADC drug JY-023.
Ref 116	Enduring biotechnology company product pipeline
Ref 117	Kangabio biotechnology company product pipeline
Ref 118	Legochem biosciences biopharmaceutical company product pipeline
Ref 119	ADC review: basic information about LCB14-15NM.
Ref 120	Legochem biosciences: Biopharmaceutical company with robust milestone potential; 2019
Ref 121	Blueshield pharma product pipeline
Ref 122	Introduction to basic information on ADC drug lead ADC (Virtuoso Therapeutics).
Ref 123	Lanova medicines biotechnology company product pipeline
Ref 124	Introduction to basic information on ADC drug LIN-003.
Ref 125	Introduction to basic information on ADC drug LP-A18.
Ref 126	Futuregen biopharmaceutical company product pipeline
Ref 127	Manhattan biotech company product pipeline
Ref 128	Adagene and ADC therapeutics announce SAFEbody license agreement; 2019
Ref 129	Introduction to basic information on ADC drug MBC-301
Ref 130	Mablink bioscience company product pipeline
Ref 131	Introduction to basic information on advanced antibody drug conjugates(Belrose Pharma).
Ref 132	Introduction to basic information on ADC drug monoclonal Antibody-Drug Conjugates(Celltrion Chemical Research Institute/Immunogen/Celltrion).
Ref 133	Kind Pharmaceuticals LLC company product pipeline.
Ref 134	Introduction to basic information on ADC drug MRG006.
Ref 135	Micurx biopharmaceutical company product pipeline
Ref 136	Introduction to basic information on ADC drug NBE-001.
Ref 137	Introduction to basic information on ADC drug NBE-003.
Ref 138	NewBio Therapeutics company product pipeline
Ref 139	NewBio Therapeutics company product pipeline
Ref 140	NewBio Therapeutics company product pipeline
Ref 141	NewBio Therapeutics company product pipeline
Ref 142	Introduction to basic information on next generation antibody-drug conjugates(Oxford BioTherapeutics).
Ref 143	Nectin therapeutics biotechnology company product pipeline
Ref 144	An overview of NW-001.
Ref 145	Introduction to basic information on ADC drug NW-12-005.
Ref 146	Neoletix biotechnology company product pipeline
Ref 147	Oxford Biotherapeutics product pipeline
Ref 148	Denali Therapeutics 2021.
Ref 149	Introduction to basic information on ADC drug OX-004.
Ref 150	Oligomerization improves endostatin as antiangi-ogenic and anticancer drug (P-1000)
Ref 151	Enduring biotechnology company product pipeline
Ref 152	Pinotbio biotechnology company product pipeline
Ref 153	Epinogen biotechnology company product pipeline
Ref 154	PrimeLink bio therapeutics product pipeline
Ref 155	PrecisemAb biotechnology company product pipeline
Ref 156	Post translational modification therapeutics product pipeline
Ref 157	Introduction to basic information on ADC drug RAD-501.
Ref 158	RemeGen biopharmaceutical company clinical-stage drug candidates and selected IND-enabling stage candidates; 30 Jun 2022.
Ref 159	Syntab therapeutics biotechnology company product pipeline
Ref 160	Next generation drug conjugates for cancer treatment.
Ref 161	Introduction to basic information on ADC drug second ADC (Virtuoso Therapeutics).
Ref 162	Research programme: glycodesigned biotherapeutics (SeeloMab-GEX)-Glycotope; 28 Mar 2018.
Ref 163	Introduction to basic information on ADC drug SGN-25.
Ref 164	Introduction to basic information on ADC drug SI-B-004A.
Ref 165	Introduction to basic information on ADC drug SI-M-002A.
Ref 166	Introduction to basic information on ADC drug SI-M-005A.
Ref 167	Introduction to basic information on ADC drug SMD-3117.
Ref 168	Sirenas biotechnology company announcement; 2016
Ref 169	Xiling yuan pharmaceutical company product pipeline
Ref 170	Antibody drug conjugates SOT107
Ref 171	Antibody drug conjugates SOT106
Ref 172	Introduction to basic information on ADC drug Spliceostatin-antibody-drug conjugate
Ref 173	F-star biotechnology company product pipeline
Ref 174	Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies; 2022
Ref 175	Symray biopharmaceutical company product pipeline
Ref 176	Introduction to basic information on ADC drug SY-1558
Ref 177	Tot biopharm annual announcement; 2021
Ref 178	Heidelberg pharma ATACs fighting cancer; 2020
Ref 179	ADC review: basic information about TGM-002.
Ref 180	ADC review: basic information about TGM-003.
Ref 181	ADC review: basic information about TGM-004.
Ref 182	ADC review: basic information about TGM-005.
Ref 183	Transcenta Holding Limited 2022 annual report.
Ref 184	Topmunnity therapeutics company product pipeline
Ref 185	https://tubulis.com/
Ref 186	Introduction to basic information on ADC drug Vas-201.
Ref 187	Introduction to basic information on ADC drug Vas-202.
Ref 188	ADC review: basic information about VIS705.
Ref 189	Introduction to basic information on ADC drug VLS-201.
Ref 190	Introduction to basic information on ADC drug VLS-301.
Ref 191	Westlake therapeutics product pipeline
Ref 192	Mersana biopharmaceutical company product pipeline
Ref 193	Evopoint biosciences product pipeline
Ref 194	ADC drug XYD-9668-198 antibody conjugating agent for injection passed the review of the State Drug Administration Drug Review Center and was granted implied permission for clinical trials.
Ref 195	Introduction to basic information on ADC drug ZV03-ADC.
Ref 196	Introduction to basic information on ADC drug Antibody drug conjugate (Asana BioSciences)
Ref 197	Compugen's antibody drug conjugate program results presented; 19 Oct 2015.
Ref 198	Five prime therapeutics licenses antibodies to seattle genetics for use in novel antibody drug conjugate (ADC) programs; 2020
Ref 199	Introduction to basic information on antibody drug conjugates(Intrexon).
Ref 200	Meditope biosciences presentation; 2014
Ref 201	Introduction to basic information on antibody drug conjugates(Sanofi).
Ref 202	Bristol-myers squibb and ambrx announce collaboration for novel biologics programs in diabetes and heart failure
Ref 203	Introduction to basic information on antibody-drug conjugates(Daiichi Sankyo).
Ref 204	Research programme: anticancer antibody drug conjugates - Advanced Proteome Therapeutics/University of Toronto; 28 Nov 2020.
Ref 205	Immunobiochem corporation partners with the centre for the commercialization of antibodies and biologics at the university of toronto to advance new antibody drug conjugates; 2016
Ref 206	University of Virginia spinoff neoantigenics announces collaboration with Pfizer, investment from CIT to develop antibody-based therapeutics for cancer; 2014
Ref 207	Introduction to basic information on ADC drug BIOO-5.
Ref 208	Introduction to basic information on ADC drug BIOO-6.
Ref 209	Introduction to basic information on ADC drug BIOO-7.
Ref 210	Introduction to basic information on ADC drug CRC-02 targeting antibody-drug conjugate(Igenica).
Ref 211	Introduction to basic information on ADC drug CYP-Ab.
Ref 212	Introduction to basic information on ADC drug LM-317.
Ref 213	ADC review: basic information about LCB14-2NM.
Ref 214	Introduction to basic information on ADC drug LIN-003.
Ref 215	Introduction to basic information on antibodies conjugated to marine-derived cytotoxic payloads(Seattle Genetics).
Ref 216	Introduction to basic information on ADC drug monovalent azymatic antibody drug conjugate(Zymeworks).
Ref 217	Introduction to basic information on ADC drug MRG005.
Ref 218	Introduction to basic information on ADC drug MRG007.
Ref 219	Introduction to basic information on ADC drug MRG008.
Ref 220	Introduction to basic information on ADC drug MRG009.
Ref 221	Introduction to basic information on ADC drug multi-functional antibody drug conjugate combination therapeutics (Sutro Biopharma/Celgene).